A Phase 1, Open-label, Randomized, 2-sequence, 4-period, Fully-replicate, Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets in Healthy Adult Participants
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs Adagrasib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Mirati Therapeutics
- 04 Feb 2025 New trial record